Connect your AI

Palvella Therapeutics PVLA Total Equity

Total Equity at other companies

Relay Therapeutics, Inc.RLAY

$642.18M-10.9%

Viridian Therapeutics, Inc.VRDN

$636.01M+5.2%

ANI PharmaceuticalsANIP

$562.3M+34.3%

PrecigenPGEN

$20.24M+244%

Arcutis Biotherapeutics, Inc.ARQT

$189.65M+32.9%

Kodiak Sciences IncKOD

$112.1M+3.0%

Other financials

Income statement

Revenue$53.0K-97.3%

Operating income-$14.9M-88.7%

Net income-$15.8M-92.6%

EPS (diluted)-$1.20-62.2%

Balance sheet

Cash & equivalents$206.4M+173%

Total debt$584.0K—

Total assets$263.8M+232%

Cash flow

Operating cash flow-$10.9M-60.5%

CapEx--100%

Free cash flow-$2.7M+72.0%

Valuation

Market cap$1.7B+468%

Enterprise value$1.5B—

P/S41.6×—

Profitability

Operating margin-183.2%-13.5pp

Net margin71.7%+40.4pp

FCF margin-99.8%-34.2pp

Returns & leverage

Return on equity-34.2%—

Debt / equity0×—

Current ratio28.9×+20.0×

Where this comes from

Reported directly by Palvella Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Palvella Therapeutics's total equity?: Palvella Therapeutics (PVLA) reported total equity of $232.31M in Q1 2026.
How has Palvella Therapeutics's total equity changed year-over-year?: Palvella Therapeutics's total equity increased by 318.0% year-over-year, from $55.58M to $232.31M.
What is the long-term trend for Palvella Therapeutics's total equity?: Over 5 years (2020 to 2025), Palvella Therapeutics's total equity has grown at a -2.0% compound annual growth rate (CAGR), from $31.03M to $27.98M.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.